Home
New Amsterdam Pharma

New Amsterdam Pharma Market Share Analysis for August 2026

Obicetrapib is a cholesteryl ester transfer protein inhibitor being investigated as a treatment in lowering low-density lipoprotein cholesterol levels.

Industry: N/A

Domainnewamsterdampharma.com

Year Founded2019

Employees51 - 200

Annual Revenue$15M - $25M

New Amsterdam Pharma

New Amsterdam Pharma (including company regionals)

newamsterdampharma.com

See more website traffic and engagement information

New Amsterdam Pharma Revenue up to August 2026 is 15M - 25M

revenue generated by New Amsterdam Pharma top domains

New Amsterdam Pharma top domains revenue over 3 years

Revenue for New Amsterdam Pharma top domains

newamsterdampharma.com15M - 25M

See more with Sales Intelligence

Total visits to New Amsterdam Pharma's top domains

Understand New Amsterdam Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

newamsterdampharma.com4.9K

See more with Sales Intelligence

Avg. visit duration in New Amsterdam Pharma's top domains

Analyze New Amsterdam Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

newamsterdampharma.com00:00:33

See more with Sales Intelligence

Avg. pageviews on New Amsterdam Pharma's top domains

See how New Amsterdam Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

newamsterdampharma.com1.91

See more with Sales Intelligence

New Amsterdam Pharma top competitors by domain

Top similar sites in August 2026, ranked by their affinity

esperion.comCompany NameEsperionEmployees201 - 500HQUnited States, Michigan, Ann ArborAnnual revenue$200M - $500MTotal visits18.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by New Amsterdam Pharma

These are the website technologies, by industry, used by New Amsterdam Pharma top domains

Advertising (3)

Google Adsense

Payment & Currencies (3)

Cart Functionality

Social (3)

Instagram

Widget (3)

Twemoji

More Technologies

10

See all

News & Signals from New Amsterdam Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNewAmsterdam Pharma Company had revenue of $3.7M on Sep 8th '26.* NewAmsterdam reported a quarterly loss of $0.52 per share, missing estimates, while revenue of $3.70 million exceeded expectations.

NewsNewAmsterdam Pharma Company is developing obicetrapib on Sep 2nd '26.In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

NewsNewAmsterdam Pharma Company attended event European Society of Cardiology (ESC) Congress 2026 on Aug 28th '26.NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 - 31, 2026 in Munich, Germany.